Similarly, Patel et al. [31] reported that VSV-IFNβ effectively targeted non-small cell lung cancer (NSCLC) both in vitro and in vivo, highlighting its therapeutic potential in lung cancer treatment. Here, IFNB1 is linked to non-small cell lung carcinoma.